Learn more about Elias Cancer Immunotherapy (ECI), a newly USDA-approved treatment for dogs with osteosarcoma. It explains how ECI works, its benefits, success rates, costs, and availability for families seeking new options in canine cancer care.

A new clinical trial led by UC Davis School of Veterinary Medicine is investigating a novel immunotherapy designed to help the immune system recognize and attack cancer cells. If proven effective, this treatment has the potential to extend survival and improve outcomes for dogs with metastatic cancer.

Dr. Jeffrey Bryan of the University of Missouri explains how the Elias Cancer Immunotherapy works, what the response rates look like, and the types of canine cancers it may treat. He also addresses eligibility, access, and potential side effects.